Getting women are obese short-changed by chemotherapy treatments?
How chemotherapy obese woman makes a request? In general, obese women with breast cancer would be reduced doses of chemotherapy as they battle breast cancer. Back in June 2005, a study published in the Archives of Internal Medicine found that obese women should receive chemotherapy based on their real women, not as a reduction of the amounts that we practice.

And now again in a study presented in August 2005, edition of the Lancet says that doctors should not reduce the doses of chemotherapy for obese women when no hormone receptors estrogen were found on breast cancer cells. This type of cancer is called estrogen-receptor negative.

Clinicians often reduce chemotherapy doses for obese patients because of concerns about how the treatment may react with the patient and have an impact on their overall health.

According to the study's director Marco Colleoni of the European Institute of Oncology, Italy, and his colleagues, reducing the first course of chemotherapy for obese patients with estrogen receptor Breast cancer is negative "prejudicial".

Colleoni and his team have studied the relationship between body mass index (BMI), a reduction of dose chemotherapy, the expression of estrogen receptors, and the results for women with pre-menopausal breast cancer by examining data from four randomized trials.

They found that 97 of 249 obese patients received less than 85 f protocol specified at the first dose chemotherapy compared with patients with normal and intermediate BMI.

Obese patients with estrogen receptor negative disease, which has received more than 85 r of the first protocol specified

dose had significantly better disease-free survival and overall survival than those who received less than 85 f normally recommended dose.

Yet the obese patients with estrogen-receptor positive breast cancer who had reduced doses of chemotherapy did not have a big difference in their results compared with those given chemotherapy recommended doses.

And contrary to the practice, the researchers also found that obese patients initially treated with doses of chemotherapy protocol did not have more toxicity than patients who received lower doses.

Dr. Marco Colleoni concluded that, "Our results suggest that for women with ER-absent or ER-low tumor, chemotherapy dose reduction should be avoided."

The message for obese women cope with cancer is to be aware of risks and your rights. Ask your doctor going to recommend lower doses of chemotherapy for you depending on your weight and ask why.
Resources: Lancet, Archives of Internal Medicine.

http://www.deoti.com